Aspiriant LLC Decreases Stock Position in VanEck Biotech ETF (NASDAQ:BBH)

Aspiriant LLC cut its stake in VanEck Biotech ETF (NASDAQ:BBH) by 2.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,237 shares of the company’s stock after selling 96 shares during the period. Aspiriant LLC’s holdings in VanEck Biotech ETF were worth $667,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Commonwealth Retirement Investments LLC purchased a new stake in shares of VanEck Biotech ETF during the 4th quarter worth $215,000. SBI Securities Co. Ltd. purchased a new stake in VanEck Biotech ETF during the 4th quarter worth about $81,000. Raymond James Financial Inc. purchased a new stake in VanEck Biotech ETF during the 4th quarter worth about $3,381,000. Independent Advisor Alliance purchased a new stake in VanEck Biotech ETF during the 4th quarter worth about $250,000. Finally, HighTower Advisors LLC lifted its holdings in VanEck Biotech ETF by 12.0% during the 4th quarter. HighTower Advisors LLC now owns 9,903 shares of the company’s stock worth $1,554,000 after buying an additional 1,058 shares during the last quarter. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Performance

BBH stock opened at $151.74 on Wednesday. VanEck Biotech ETF has a fifty-two week low of $135.34 and a fifty-two week high of $183.64. The business has a 50 day moving average price of $148.21 and a 200 day moving average price of $156.49.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.